Weiss Asset Management LP sold TBPH

September 23, 2026 · Form 4 insider transaction

Weiss Asset Management LP sold 7,457,060 shares of Theravance Biopharma Inc at $17.00 per share, a transaction worth $126.77M. The trade was recorded as j and disclosed on an SEC Form 4, filed 5 days after the transaction.

Direction
Disposed (sell-side)
Shares
7,457,060
Price
$17.00
Total value
$126.77M
Role—
SecurityOrdinary Share $0.00001 Par Value
Transaction codeJ: J
Transaction dateSeptember 23, 2026
Filing dateSeptember 28, 2026
Shares owned after0
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each Ordinary Share $0.00001 Par Value of the Issuer held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.; Shares reported herein represent shares beneficially owned by two private investment funds for which Weiss Asset Management LP serves as investment manager. WAM GP LLC is the general partner of Weiss Asset Management LP and Andrew Weiss is the Manager of WAM GP LLC. All of Weiss Asset Management LP, WAM GP LLC, and Andrew Weiss disclaim beneficial ownership of the shares reported herein except to the extent of their pecuniary interest therein.; Represents the cash portion of the consideration paid to shareholders upon the closing of the Merger.

View the original Form 4 on SEC EDGAR